DR. PURVA VALVEKAR

DR.SAROJ SAHDEV

Abstract

To investigate the efficacy, safety, and anatomical outcomes associated with intravitreal anti-VEGF in treatment of ROP. A retrospective study of 24 infants diagnosed with stage 3 ROP, primarily treated with intravitreal Ranibizumab (IVR). Mean birth weight of babies was 1.47 ± 0.32 kg. Gestational age at birth was 32.25 ± 1.32 weeks, and post-menstrual age at treatment was 36.08± 1.61 weeks. AP-ROP was found in 41.7% of subjects. Mean follow-up was 9.58± 1.97 months. Treatment success defined as complete regression of retinopathy and vascularization into zone 3. Treatment success was observed in 36/48 eyes (75%) with primary intervention only. Remaining six infants [12/48 eyes (25%)] required secondary laser to achieve treatment success. Retreatment occurred at a mean of 7.8 weeks after initial IVR treatment (range 6-10 weeks). Intravitreal anti-VEGF treatment of ROP with ranibizumab achieved stable retinal vascularization with a low rate of complications and recurrence.